Burt Ensley Ph.D., Science Advisory Board, Chair

Burt Ensley, Ph.D., is the founder of Protein Genomics, Inc. and DermaPlus, Inc.,  Arizona-based biotechnology companies involved in wound healing, tissue regeneration and skin care. His professional career began in 1981 when he was hired by Amgen, Inc., a start-up biotech firm in Thousand Oaks, Calif., that he helped become the largest such company in the world within 10 years.  Amgen now has 40,000 employees and $12 billion in annual revenue.

In 1989, Dr. Ensley left Amgen to serve as director of advanced technologies for Envirogen, Inc. There, he led research and field demonstrations of biological and physical/chemical technologies for the treatment of hazardous wastes from the Company’s inception until its Public offering in 1992. He then became a founder and the President, CEO and Director of Phytotech, Inc., a biotechnology company using plants for the treatment of contaminated soil and water. He raised financing for Phytotech of $5 million in equity and $2 million in debt from inception to sale of the business in June 1999.

In 1999, Dr. Ensley founded Nucycle Therapy, Inc. a biotechnology company involved in discovering, developing and commercializing unique nutritional supplements and high value nutraceutical and therapeutic products from plants. He served as the Company’s CEO from from 1999 to 2001. The Company was able to scale-up the manufacture of 50 million doses of plant-based nutritional mineral supplements, and was sold to Integrated Biopharma, a publicly traded entity, in 2001.

Dr. Ensley was elected to Fellowship in the American Academy of Microbiology in recognition of his research accomplishments.  His professional affiliations have included membership in the Board of Directors and Co-Chair of The BIO5 Institute at the University of Arizona; Board of Trustees at the Biotechnology Council of New Jersey; Board of Directors of the Natural History Museum at the University of Kansas; the American Association for the Advancement of Science; the American Society for Microbiology; service on the National Research Council Committee on Catalysis; and on the Biology Directorate Advisory Committee of the National Science Foundation. He is an Adjunct Professor at Northern Arizona University.

He holds his Ph.D. degree in microbiology from the University of Georgia (1979), his master’s degree in biology from the University of New Mexico (1976), and bachelor’s degree in biology from the University of New Mexico (1974).

Dr. Ensley has 30 publications in the peer-reviewed scientific literature and holds 20 issued and 2 pending US patents.

Dr. Ensley served in the US Army from August 1968 until May, 1971, graduating from the MACV Recondo School and serving with the 5th Special Forces Group, 1st Special Forces (Airborne) in Nha Trang, Vietnam.  He was decorated twice (BSM and ARCOM) for service in combat.

He currently resides in Sedona, Ariz., with his wife, Carolyn, and their four cats. In his spare time, he enjoys gardening, cooking and tinkering with old cars.


Badylak 102 - Headshot.jpg

Dr. Stephen F. Badylak, DVM, Ph.D., MD

Dr. Stephen Badylak, DVM, PhD, MD is a Professor in the Department of Surgery, and Deputy Director of the McGowan Institute for Regenerative Medicine at the University of Pittsburgh.

Dr. Badylak has practiced both veterinary and human medicine, and is now fully engaged in research. Dr. Badylak began his academic career at Purdue University in 1983, and subsequently held a variety of positions including service as the Director of the Hillenbrand Biomedical Engineering Center from 1995-1998.

Dr. Badylak holds over 60 U.S. patents, 300 patents worldwide, has authored more than 350 scientific publications and 40 book chapters, and has recently edited a textbook entitled “Host Response to Biomaterials”. He has served as the Chair of several study sections at the National Institutes of Health (NIH), and is currently a member of the College of Scientific Reviewers for NIH. Dr. Badylak has either chaired or been a member of the Scientific Advisory Board to several major medical device companies. More than eight million patients have been treated with bioscaffolds developed in Dr. Badylak’s laboratory.

Dr. Badylak is a Fellow of the American Institute for Medical and Biological Engineering, a member of the Society for Biomaterials, a charter member of the Tissue Engineering Society International, a past president of the Tissue Engineering Regenerative Medicine International Society (TERMIS) and a Founding International Fellow of TERMIS.

Dr. Badylak's major research interests include:

  • Naturally Occurring Biomaterials, including Extracellular Matrix, and Biomaterial/Tissue

  • Developmental Biology and its Relationship to Regenerative Medicine

  • Relationship of the Innate Immune Response to Tissue Regeneration

  • Clinical Translation of Regenerative Medicine

  • Whole Organ and Tissue Reconstruction and Regeneration

Stu Williams.jpeg

Dr. Stuart Williams Ph.D.

Dr. Stuart Williams received his Ph.D. in Cell Biology from the University of Delaware followed by postdoctoral training in Pathology at the Yale School of Medicine.  During the period 1980 to 1990 he held a faculty appointment at Jefferson Medical College where he was Director of Research in the Department of Surgery.   In 1990 Dr. Williams joined the faculty at the University of Arizona and founded the University of Arizona Biomedical Engineering Program creating a research and educational link between the Medical School and College of Engineering. He held faculty positions jointly in Biomedical Engineering, Surgery, Physiology and Materials Science and Engineering.   In 2007 Dr. Williams was selected as the Scientific Director of the newly established Cardiovascular Innovation Institute, a partnership between Jewish Hospital and the University of Louisville in Louisville Kentucky.  He recently established the Bioficial Organs Program to create human tissues and organs for clinical therapeutics and in vitro drug testing using a patient’s own cells.  Central to this effort is the use of 3D bioprinting technologies.  

Dr. Williams’ research interests have focused on medical devices and regenerative medicine. He developed and patented the first methods to use fat-derived stem and regenerative cells for therapeutic use. Dr. Williams has authored over 400 scientific publications including scientific papers, abstracts, book chapters and editorials.  His entrepreneurial spirit has resulted in 23 issued US patents with numerous patents pending.  He has founded several biotechnology companies; maintained active managerial positions and has been an active consultant to the medical device, regenerative medicine and pharmaceutical community.  He is a Fellow of the American Heart Association and a Fellow of the American Institute of Medical and Biological Engineering.